<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02262156</url>
  </required_header>
  <id_info>
    <org_study_id>49/06</org_study_id>
    <secondary_id>U1111-1158-3147</secondary_id>
    <nct_id>NCT02262156</nct_id>
  </id_info>
  <brief_title>CBT Versus Selective Serotonin Reuptake Inhibitor For Treatment Of Depression In Temporal Lobe Epilepsy Patients</brief_title>
  <acronym>CBTvsSSRI</acronym>
  <official_title>Treatment Of Depression In Patients With Temporal Lobe Epilepsy: Comparative Study Of Cognitive Behavioral Therapy Vs. Selective Serotonin Reuptake Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effect of group-cognitive-behavioral therapy
      (CBT)versus treatment as usual with the selective serotonin reuptake inhibitor sertraline, in
      patients with diagnosis of temporal lobe epilepsy (TLE) and depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients with temporal lobe epilepsy and depression will be enrolled into one of two
      treatment modality. The first group will receive 12 group cognitive behavioral sessions. CBT
      is a psychotherapy focused on the recognition and change of distorted thoughts and
      maladaptive behaviors.

      The second group will receive treatment with the selective serotonin reuptake inhibitor
      sertraline or citalopram for 12 weeks. This antidepressant is wide used to treat depression
      in patients with TLE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Beck Depression Inventory score</measure>
    <time_frame>baseline, 6 weeks and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Epilepsy Scale</measure>
    <time_frame>baseline, 6 weeks and 12 weeks</time_frame>
    <description>the quality of life in epilepsy scale measures the patients perceived quality of life. Higher score indicates better quality of life. score goes from 0 to 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital anxiety and depression scale (HADS)</measure>
    <time_frame>baseline, 4weeks and 12 weeks</time_frame>
    <description>the HADS measures severity of symptoms of anxiety and depression. Lower scores indicates less symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Depression</condition>
  <condition>Epilepsy, Temporal Lobe</condition>
  <arm_group>
    <arm_group_label>Cognitive behavioral Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBT program to be used in group modality that focused on managing symptoms of depression in patients with epilepsy.
12 CBT sessions, consisting of one weekly 90-minute session for 12 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective serotonin euptake inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a SSRI (sertraline or citalopram) for 12 weeks. Dose will be adjusted every 4 weeks according to medical criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive behavioral therapy</intervention_name>
    <description>The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.
The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention</description>
    <arm_group_label>Cognitive behavioral Therapy</arm_group_label>
    <other_name>CBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI</intervention_name>
    <description>Patients will receive the &quot;treatment as usual&quot; with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned.</description>
    <arm_group_label>Selective serotonin euptake inhibitor</arm_group_label>
    <other_name>selective serotonin reuptake inhibitor</other_name>
    <other_name>antidepressant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With Major depressive disorder according to criteria from the fourth edition of the
             Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)

          -  Diagnosed with TLE according to the criteria of the International League Against
             Epilepsy

          -  Literates had sign an informed consent

          -  Patients on antidepressant treatments will be allowed to participate only if they had
             been at stable doses for more than 8 weeks and still show signs of significant
             depression

        Exclusion Criteria:

          -  Patients with high risk of suicide who required hospitalization

          -  Patients who abused or are dependent on drugs

          -  Those with a history of head trauma six months prior to the interview

          -  Patients who have any condition that would prevent them from understanding the study
             or the psychotherapeutic process, such as mental retardation, psychosis, delirium,
             dementia, etc

          -  Patients who have previously received CBT

          -  Patients who have started, an antidepressant drug the last 8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Crail-Melendez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Neurología y Neurocirugía MVS</name>
      <address>
        <city>MExico</city>
        <state>D.f.</state>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez</investigator_affiliation>
    <investigator_full_name>Edgar Daniel Crail Melendez</investigator_full_name>
    <investigator_title>Md</investigator_title>
  </responsible_party>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <keyword>Selective serotonin reuptake inhibitor</keyword>
  <keyword>depression</keyword>
  <keyword>epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Temporal Lobe</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

